Pharmacotherapeutics for Advanced Practice: 200
Practice Questions with Correct Answers & Detailed
Explanations | 2026-2027 | Graded A+ Verified
Solutions | Complete Study Guide for NP Certification
Section 1: Pharmacokinetics & Pharmacodynamics
(Questions 1–25)
1. A 75-year-old patient is prescribed a medication that is primarily renally
excreted. Which of the following pharmacokinetic changes in the elderly requires
a dosage adjustment?
A. Decreased gastric motility
B. Decreased hepatic blood flow
C. Decreased glomerular filtration rate (GFR)
D. Increased volume of distribution for lipophilic drugs
Answer: C. Decreased glomerular filtration rate (GFR)
Explanation: Age-related decline in renal function (decreased GFR) is the most significant
pharmacokinetic change affecting drug excretion in older adults. Medications that are
primarily renally excreted (e.g., digoxin, lithium, aminoglycosides, many antibiotics)
require dose adjustment based on creatinine clearance. Decreased gastric motility
affects absorption, decreased hepatic blood flow affects metabolism, and increased
volume of distribution affects lipophilic drugs, but renal excretion is the primary concern
for renally cleared medications.
,2. Which of the following best describes the mechanism of action of a competitive
antagonist?
A. Binds to the same receptor site as the agonist and produces a maximal response
B. Binds to the same receptor site as the agonist but produces no response, blocking the
agonist
C. Binds to a different receptor site and enhances the agonist's effect
D. Binds to a different receptor site and produces an opposite effect
Answer: B. Binds to the same receptor site as the agonist but produces no
response, blocking the agonist
Explanation: A competitive antagonist binds reversibly to the same receptor site as the
agonist, preventing the agonist from binding and producing a response. The
antagonism can be overcome by increasing the concentration of the agonist. This is in
contrast to noncompetitive antagonists, which bind to a different site and cannot be
overcome by increasing agonist concentration.
3. A patient with hepatic cirrhosis has decreased liver function. Which
pharmacokinetic process is most likely to be affected?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: C. Metabolism
Explanation: Liver cirrhosis impairs the liver's ability to metabolize drugs, leading to
increased drug half-life, accumulation, and risk of toxicity. Doses of drugs metabolized
by the liver may need to be reduced. Excretion (primarily renal) may be affected if there
,is concurrent kidney disease, but metabolism is the primary concern in liver disease.
Drugs with high first-pass metabolism (e.g., propranolol, morphine) may have increased
bioavailability.
4. A patient is taking a highly protein-bound medication. Which condition would
increase the risk of toxicity due to increased free drug levels?
A. Hypoalbuminemia
B. Hyperalbuminemia
C. Dehydration
D. Polycythemia
Answer: A. Hypoalbuminemia
Explanation: Drugs that are highly protein-bound (e.g., warfarin, phenytoin, valproic
acid) are primarily bound to albumin. In hypoalbuminemia (low albumin levels), there is
less protein available for binding, resulting in higher free (unbound) drug
concentrations, which can lead to increased therapeutic effect and toxicity. This is
especially important in older adults, malnourished patients, and those with liver disease.
5. The half-life (t½) of a drug is 12 hours. Approximately how long will it take for
the drug to reach steady-state concentration?
A. 12 hours
B. 24 hours
C. 48 hours
D. 60 hours
, Answer: D. 60 hours
Explanation: Steady-state concentration is achieved after approximately 4-5 half-lives.
For a drug with a 12-hour half-life, steady state is reached in about 48-60 hours (4-5 ×
12 hours = 48-60 hours). At steady state, drug administration and drug elimination are
balanced, resulting in consistent drug levels. This principle is used to determine dosing
intervals and loading doses.
6. Which of the following factors increases the volume of distribution (Vd) of a
drug?
A. High protein binding
B. Low lipid solubility
C. High lipid solubility
D. Large molecular size
Answer: C. High lipid solubility
Explanation: Volume of distribution (Vd) is increased by high lipid solubility, which
allows the drug to distribute extensively into tissues. Highly lipid-soluble drugs (e.g.,
anesthetics, benzodiazepines, digoxin) have large Vd. Highly protein-bound drugs tend
to have lower Vd because they remain in the plasma compartment. A large Vd indicates
extensive tissue distribution and a long elimination half-life.
7. A patient with renal impairment has a decreased GFR. Which of the following
medications would require the most significant dose adjustment?
Practice Questions with Correct Answers & Detailed
Explanations | 2026-2027 | Graded A+ Verified
Solutions | Complete Study Guide for NP Certification
Section 1: Pharmacokinetics & Pharmacodynamics
(Questions 1–25)
1. A 75-year-old patient is prescribed a medication that is primarily renally
excreted. Which of the following pharmacokinetic changes in the elderly requires
a dosage adjustment?
A. Decreased gastric motility
B. Decreased hepatic blood flow
C. Decreased glomerular filtration rate (GFR)
D. Increased volume of distribution for lipophilic drugs
Answer: C. Decreased glomerular filtration rate (GFR)
Explanation: Age-related decline in renal function (decreased GFR) is the most significant
pharmacokinetic change affecting drug excretion in older adults. Medications that are
primarily renally excreted (e.g., digoxin, lithium, aminoglycosides, many antibiotics)
require dose adjustment based on creatinine clearance. Decreased gastric motility
affects absorption, decreased hepatic blood flow affects metabolism, and increased
volume of distribution affects lipophilic drugs, but renal excretion is the primary concern
for renally cleared medications.
,2. Which of the following best describes the mechanism of action of a competitive
antagonist?
A. Binds to the same receptor site as the agonist and produces a maximal response
B. Binds to the same receptor site as the agonist but produces no response, blocking the
agonist
C. Binds to a different receptor site and enhances the agonist's effect
D. Binds to a different receptor site and produces an opposite effect
Answer: B. Binds to the same receptor site as the agonist but produces no
response, blocking the agonist
Explanation: A competitive antagonist binds reversibly to the same receptor site as the
agonist, preventing the agonist from binding and producing a response. The
antagonism can be overcome by increasing the concentration of the agonist. This is in
contrast to noncompetitive antagonists, which bind to a different site and cannot be
overcome by increasing agonist concentration.
3. A patient with hepatic cirrhosis has decreased liver function. Which
pharmacokinetic process is most likely to be affected?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Answer: C. Metabolism
Explanation: Liver cirrhosis impairs the liver's ability to metabolize drugs, leading to
increased drug half-life, accumulation, and risk of toxicity. Doses of drugs metabolized
by the liver may need to be reduced. Excretion (primarily renal) may be affected if there
,is concurrent kidney disease, but metabolism is the primary concern in liver disease.
Drugs with high first-pass metabolism (e.g., propranolol, morphine) may have increased
bioavailability.
4. A patient is taking a highly protein-bound medication. Which condition would
increase the risk of toxicity due to increased free drug levels?
A. Hypoalbuminemia
B. Hyperalbuminemia
C. Dehydration
D. Polycythemia
Answer: A. Hypoalbuminemia
Explanation: Drugs that are highly protein-bound (e.g., warfarin, phenytoin, valproic
acid) are primarily bound to albumin. In hypoalbuminemia (low albumin levels), there is
less protein available for binding, resulting in higher free (unbound) drug
concentrations, which can lead to increased therapeutic effect and toxicity. This is
especially important in older adults, malnourished patients, and those with liver disease.
5. The half-life (t½) of a drug is 12 hours. Approximately how long will it take for
the drug to reach steady-state concentration?
A. 12 hours
B. 24 hours
C. 48 hours
D. 60 hours
, Answer: D. 60 hours
Explanation: Steady-state concentration is achieved after approximately 4-5 half-lives.
For a drug with a 12-hour half-life, steady state is reached in about 48-60 hours (4-5 ×
12 hours = 48-60 hours). At steady state, drug administration and drug elimination are
balanced, resulting in consistent drug levels. This principle is used to determine dosing
intervals and loading doses.
6. Which of the following factors increases the volume of distribution (Vd) of a
drug?
A. High protein binding
B. Low lipid solubility
C. High lipid solubility
D. Large molecular size
Answer: C. High lipid solubility
Explanation: Volume of distribution (Vd) is increased by high lipid solubility, which
allows the drug to distribute extensively into tissues. Highly lipid-soluble drugs (e.g.,
anesthetics, benzodiazepines, digoxin) have large Vd. Highly protein-bound drugs tend
to have lower Vd because they remain in the plasma compartment. A large Vd indicates
extensive tissue distribution and a long elimination half-life.
7. A patient with renal impairment has a decreased GFR. Which of the following
medications would require the most significant dose adjustment?
